[go: up one dir, main page]

WO2014057432A3 - Nanoparticules lipidiques à multicomposant et leurs procédés de préparation - Google Patents

Nanoparticules lipidiques à multicomposant et leurs procédés de préparation Download PDF

Info

Publication number
WO2014057432A3
WO2014057432A3 PCT/IB2013/059230 IB2013059230W WO2014057432A3 WO 2014057432 A3 WO2014057432 A3 WO 2014057432A3 IB 2013059230 W IB2013059230 W IB 2013059230W WO 2014057432 A3 WO2014057432 A3 WO 2014057432A3
Authority
WO
WIPO (PCT)
Prior art keywords
processes
preparation
lipid nanoparticles
multicomponent lipid
multicomponent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2013/059230
Other languages
English (en)
Other versions
WO2014057432A9 (fr
WO2014057432A2 (fr
Inventor
Giulio CARACCIOLO
Daniela POZZI
Simona MARCHINI
Augusto Amici
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universita degli Studi di Camerino
Universita degli Studi di Roma La Sapienza
Original Assignee
Universita degli Studi di Camerino
Universita degli Studi di Roma La Sapienza
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universita degli Studi di Camerino, Universita degli Studi di Roma La Sapienza filed Critical Universita degli Studi di Camerino
Publication of WO2014057432A2 publication Critical patent/WO2014057432A2/fr
Publication of WO2014057432A9 publication Critical patent/WO2014057432A9/fr
Publication of WO2014057432A3 publication Critical patent/WO2014057432A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne de nouvelles nanoparticules lipidiques à multicomposant pour le transport non viral d'acides nucléiques et/ou de médicaments antitumoraux, et leurs procédés de préparation, et leur utilisation en thérapie génique et/ou thérapie antitumorale.
PCT/IB2013/059230 2012-10-09 2013-10-09 Nanoparticules lipidiques à multicomposant et leurs procédés de préparation Ceased WO2014057432A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITRM2012A000480 2012-10-09
IT000480A ITRM20120480A1 (it) 2012-10-09 2012-10-09 Nanoparticelle lipidiche multicomponenti e procedimenti per la loro preparazione.

Publications (3)

Publication Number Publication Date
WO2014057432A2 WO2014057432A2 (fr) 2014-04-17
WO2014057432A9 WO2014057432A9 (fr) 2014-05-30
WO2014057432A3 true WO2014057432A3 (fr) 2014-07-24

Family

ID=47278447

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2013/059230 Ceased WO2014057432A2 (fr) 2012-10-09 2013-10-09 Nanoparticules lipidiques à multicomposant et leurs procédés de préparation

Country Status (2)

Country Link
IT (1) ITRM20120480A1 (fr)
WO (1) WO2014057432A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107106703A (zh) * 2014-11-25 2017-08-29 纳米生物技术公司 药物组合物、其制备和用途

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014123935A1 (fr) 2013-02-05 2014-08-14 1Globe Health Institute Llc Nanoparticules biodégradables et cliniquement compatibles en tant que véhicules d'administration de médicament
BR112015029853A2 (pt) 2013-05-30 2017-07-25 Nanobiotix uso de uma composição farmacêutica
US9504405B2 (en) 2013-10-23 2016-11-29 Verily Life Sciences Llc Spatial modulation of magnetic particles in vasculature by external magnetic field
US10542918B2 (en) 2013-10-23 2020-01-28 Verily Life Sciences Llc Modulation of a response signal to distinguish between analyte and background signals
PT3229776T (pt) 2014-11-25 2023-08-17 Curadigm Sas Composição farmacêutica combinando pelo menos duas nanopartícuas distintas e um composto farmacêutico, preparaçâo e suas utilizações
CA2968473A1 (fr) * 2014-11-25 2016-06-02 Nanobiotix Composition pharmaceutique, sa preparation et ses utilisations
LT3223796T (lt) 2014-11-25 2021-10-25 Curadigm Sas Farmacinės kompozicijos, jų gamyba ir panaudojimo būdai
PL3229843T3 (pl) 2014-11-25 2020-06-29 Curadigm Sas Kompozycja farmaceutyczna, wytwarzanie i zastosowanie tej kompozycji
US9861710B1 (en) 2015-01-16 2018-01-09 Verily Life Sciences Llc Composite particles, methods, and in vivo diagnostic system
WO2016141167A1 (fr) 2015-03-03 2016-09-09 Cureport, Inc. Formulations pharmaceutiques liposomales en combinaison
WO2016141161A1 (fr) 2015-03-03 2016-09-09 Cureport, Inc. Formulations pharmaceutiques liposomales à double charge
EA201792560A1 (ru) 2015-05-28 2018-06-29 Нанобиотикс Наночастицы для применения в качестве терапевтической вакцины
ES2755418T3 (es) 2015-11-17 2020-04-22 Bioncotech Therapeutics S L Novedosa composición farmacéutica que comprende partículas que comprenden un complejo de un polirribonucleótido de doble cadena y una polialquilenimina
ES2924138T3 (es) 2017-05-17 2022-10-04 Highlight Therapeutics S L Nueva composición farmacéutica que comprende partículas que comprenden un complejo de un polirribonucleótido de doble cadena y una polialquilenimina
TWI894123B (zh) * 2017-12-27 2025-08-21 日商武田藥品工業有限公司 含核酸之脂質奈米粒子及其用途
AU2020316335A1 (en) * 2019-07-19 2022-02-17 University Of Florida Research Foundation, Incorporated Multilamellar RNA nanoparticles
CN110882383A (zh) * 2019-11-26 2020-03-17 宁夏医科大学 一种阳离子脂质体-鱼精蛋白-mRNA肿瘤疫苗及其制备方法和应用方法
US20230096704A1 (en) * 2020-02-05 2023-03-30 University Of Florida Research Foundation, Incorporated Rna-loaded nanoparticles and use thereof for the treatment of cancer
AU2021273502A1 (en) * 2020-05-15 2023-02-02 Translate Bio, Inc. Lipid nanoparticle formulations for mRNA delivery
CN111603571A (zh) * 2020-05-28 2020-09-01 中国药科大学 线粒体靶向类脂质载体Mito-Aliposome、其复合物，制备方法和用途
CN113577039A (zh) * 2021-07-01 2021-11-02 温州医科大学附属第二医院（温州医科大学附属育英儿童医院） 鱼精蛋白压缩dna后被红细胞膜包裹构成的纳米颗粒的应用及其制备方法
CN114657147B (zh) * 2022-01-27 2023-12-01 安徽智飞龙科马生物制药有限公司 一种生物材料的保护剂及其应用
CN114699538A (zh) * 2022-04-02 2022-07-05 中国药科大学 一种核-壳式高效基因药物递送系统及其制备方法
EP4626409A1 (fr) * 2022-12-01 2025-10-08 Generation Bio Co. Compositions d'acide nucléique simple brin synthétique et procédés associés
CN116712408B (zh) * 2023-06-28 2024-04-16 广州国家实验室 一种脂质纳米颗粒及其制备方法与应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010043630A2 (fr) * 2008-10-13 2010-04-22 Sigmoid Pharma Limited Système d'administration d'arn
WO2012112730A2 (fr) * 2011-02-15 2012-08-23 Merrimack Pharmaceuticals, Inc. Compositions et procédés pour délivrer un acide nucléique à une cellule

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010043630A2 (fr) * 2008-10-13 2010-04-22 Sigmoid Pharma Limited Système d'administration d'arn
WO2012112730A2 (fr) * 2011-02-15 2012-08-23 Merrimack Pharmaceuticals, Inc. Compositions et procédés pour délivrer un acide nucléique à une cellule

Non-Patent Citations (13)

* Cited by examiner, † Cited by third party
Title
CARACCIOLO ET AL: "Transfection efficiency boost by designer multicomponent lipoplexes", BIOCHIMICA ET BIOPHYSICA ACTA (BBA) - BIOMEMBRANES, ELSEVIER, AMSTERDAM, NL, vol. 1768, no. 9, 14 September 2007 (2007-09-14), pages 2280 - 2292, XP022244094, ISSN: 0005-2736, DOI: 10.1016/J.BBAMEM.2007.06.027 *
CARACCIOLO GIULIO ET AL: "DNA release from cationic liposome/DNA complexes by anionic lipids", APPLIED PHYSICS LETTERS, AIP, AMERICAN INSTITUTE OF PHYSICS, MELVILLE, NY, US, vol. 89, no. 23, 5 December 2006 (2006-12-05), pages 233903 - 233903, XP012087536, ISSN: 0003-6951, DOI: 10.1063/1.2399356 *
CARACCIOLO GIULIO ET AL: "On the correlation between phase evolution of lipoplexes/anionic lipid mixtures and DNA release", APPLIED PHYSICS LETTERS, AIP, AMERICAN INSTITUTE OF PHYSICS, MELVILLE, NY, US, vol. 91, no. 14, 4 October 2007 (2007-10-04), pages 143903 - 143903, XP012099609, ISSN: 0003-6951, DOI: 10.1063/1.2794436 *
CHEN J ET AL: "Transfection efficiency and intracellular fate of polycation liposomes combined with protamine", BIOMATERIALS, ELSEVIER SCIENCE PUBLISHERS BV., BARKING, GB, vol. 32, no. 5, 1 February 2011 (2011-02-01), pages 1412 - 1418, XP027537940, ISSN: 0142-9612, [retrieved on 20101102] *
COLONNA C ET AL: "Non-viral dried powders for respiratory gene delivery prepared by cationic and chitosan loaded liposomes", INTERNATIONAL JOURNAL OF PHARMACEUTICS, ELSEVIER BV, NL, vol. 364, no. 1, 19 November 2008 (2008-11-19), pages 108 - 118, XP025562425, ISSN: 0378-5173, [retrieved on 20080819], DOI: 10.1016/J.IJPHARM.2008.07.034 *
D. POZZI ET AL: "Mechanistic evaluation of the transfection barriers involved in lipid-mediated gene delivery: Interplay between nanostructure and composition", BIOCHIMICA ET BIOPHYSICA ACTA (BBA) - BIOMEMBRANES, vol. 1838, no. 3, 1 March 2014 (2014-03-01), pages 957 - 967, XP055107607, ISSN: 0005-2736, DOI: 10.1016/j.bbamem.2013.11.014 *
D. POZZI ET AL: "Mechanistic Understanding of Gene Delivery Mediated by Highly Efficient Multicomponent Envelope-Type Nanoparticle Systems", MOLECULAR PHARMACEUTICS, vol. 10, no. 12, 2 December 2013 (2013-12-02), pages 4654 - 4665, XP055106503, ISSN: 1543-8384, DOI: 10.1021/mp400470p *
GIULIO CARACCIOLO ET AL: "Efficient Escape from Endosomes Determines the Superior Efficiency of Multicomponent Lipoplexes", THE JOURNAL OF PHYSICAL CHEMISTRY B, vol. 113, no. 15, 16 April 2009 (2009-04-16), pages 4995 - 4997, XP055069393, ISSN: 1520-6106, DOI: 10.1021/jp811423r *
GIULIO CARACCIOLO ET AL: "Factors determining the superior performance of lipid/DNA/protammine nanoparticles over lipoplexes", JOURNAL OF MEDICINAL CHEMISTRY, 13 May 2011 (2011-05-13), pages 4160 - 4171, XP055069350, Retrieved from the Internet <URL:http://pubs.acs.org/doi/ipdf/10.1021/jm200237p> [retrieved on 20130703] *
MING-KUNG YEH ET AL: "Clinical development of liposome based drugs: formulation, characterization, and therapeutic efficacy", INTERNATIONAL JOURNAL OF NANOMEDICINE, 1 December 2011 (2011-12-01), pages 49, XP055069345, DOI: 10.2147/IJN.S26766 *
POZZI DANIELA ET AL: "Programmed packaging of multicomponent envelope-type nanoparticle system for gene delivery", APPLIED PHYSICS LETTERS, AIP, AMERICAN INSTITUTE OF PHYSICS, MELVILLE, NY, US, vol. 96, no. 18, 5 May 2010 (2010-05-05), pages 183702 - 183702, XP012131040, ISSN: 0003-6951, DOI: 10.1063/1.3427354 *
SARDER NASIR UDDIN: "Cationic lipids used in non-viral gene delivery systems", BIOTECHNOLOGY AND MOLECULAR BIOLOGY REVIEW, vol. 2, no. 3, 1 August 2007 (2007-08-01), pages 58 - 67, XP055069508 *
SIMONA MOTTA: "Nanoparticles systems for gene delivery interacting with model cell membranes: a structural study", FISMAT2013, 1 July 2013 (2013-07-01), XP055108194, Retrieved from the Internet <URL:http://www.fisi.polimi.it/it/fismat2013/submission/view/409> [retrieved on 20140317] *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107106703A (zh) * 2014-11-25 2017-08-29 纳米生物技术公司 药物组合物、其制备和用途

Also Published As

Publication number Publication date
WO2014057432A9 (fr) 2014-05-30
ITRM20120480A1 (it) 2014-04-10
WO2014057432A2 (fr) 2014-04-17

Similar Documents

Publication Publication Date Title
WO2014057432A3 (fr) Nanoparticules lipidiques à multicomposant et leurs procédés de préparation
IL289934B (en) Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids
IL286515A (en) Novel lipids and nanoparticle formulations of lipids for delivery of nucleic acids
IL283545A (en) Lipids and nanoparticulate lipid formulations for delivery of nucleic acids
WO2013170170A3 (fr) Compositions et méthodes de thérapie génique
WO2013028942A8 (fr) Ciblage de microbulles
MX2019005287A (es) Lipidos cationicos para suministro de acido nucleico y su preparacion.
WO2012116073A3 (fr) Dendron-hélices amphiphiles, micelles de ceux-ci et utilisations
PH12015500758A1 (en) Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases
IL231536A (en) Indazole-3-carboxamides, pharmaceuticals containing them and their use in the treatment of diseases
EP3033113A4 (fr) Nouvelle nanotechnologie d&#39;auto-assemblage de polyéthylènimine modifiée par plga
EP3212221A4 (fr) Admnistration efficace de molécules thérapeutiques in vitro et in vivo
EP3204032A4 (fr) Administration efficace de molécules thérapeutiques in vitro et in vivo
SG11201502455TA (en) Fgfr3 fusion gene and pharmaceutical drug targeting same
WO2014145159A3 (fr) Anticorps à charge génétiquement modifiée ou compositions de protéines de ciblage à pénétration améliorée et méthodes d&#39;utilisation
WO2013084000A3 (fr) Exosomes pour l&#39;administration de biothérapiques
IL226205B (en) Fusion proteins, pharmaceutical preparations containing them and their use in the preparation of drugs for the treatment of cancer
IN2014MN01886A (fr)
EP2880160A4 (fr) Isolation de mutants améliorant le transport de protéine d&#39;administration de médicament
WO2013190509A3 (fr) Préparation d&#39;intermédiaires du bocéprévir
IL255229A (en) Anionic nanoparticles for use in the delivery of anionic small molecule drugs
WO2014104989A8 (fr) Compositions pharmaceutiques comprenant de l&#39;aripiprazole
WO2013127539A3 (fr) Formulations pharmaceutiques
HK1263170A1 (en) Lipids and lipid nanoparticle formulations for delivery of nucleic acids
WO2013109213A3 (fr) Formulations pharmaceutiques comprenant du tiotropium

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13812096

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 13812096

Country of ref document: EP

Kind code of ref document: A2